The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060611" target="_blank" >RIV/00216224:14110/12:00060611 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.lungcan.2012.05.075" target="_blank" >http://dx.doi.org/10.1016/j.lungcan.2012.05.075</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.lungcan.2012.05.075" target="_blank" >10.1016/j.lungcan.2012.05.075</a>
Alternative languages
Result language
angličtina
Original language name
The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)
Original language description
This analysis, The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients, presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů